What type of drug does Semaglutide Injection belong to?

Semaglutide injection (Wegovy) is a GLP-1 receptor agonist, a glucagon-like peptide-1 analogue. It acts on the area of u200bu200bthe brain that regulates appetite by simulating the natural hormone GLP-1 secreted by the human intestine, helping patients control food intake while improving insulin secretion. Semaglutide was originally developed to treat type 2 diabetes. Its mechanism of action is to enhance insulin secretion and inhibit glucagon release, thereby lowering blood sugar. As the research deepened, scientists discovered that the drug showed unique effects in suppressing appetite and weight management, so they developed a brand for obesity treatment-Wegovy.

From a pharmacological perspective, Wegovy belongs to the same class of GLP-1 agonists as similar drugs such as liraglutide (Saxenda), but has been optimized in terms of molecular structure and duration of drug effect. Wegovy is a long-acting preparation that can be injected once a week to maintain stable blood concentrations, while Saxenda requires daily injections. The long-acting design significantly improves medication compliance, making it easier for patients to adhere to treatment. Its main mechanism of action includes three aspects: slowing down gastric emptying, making people feel fuller more easily; suppressing appetite through the central nervous system; and regulating pancreatic beta cell function to improve glucose tolerance. Together, these effects promote weight loss and metabolic improvements.

In clinical application, Wegovy is mainly used for obese or overweight people, especially for adults with a BMI ≥ 30, or patients with a BMI ≥ 27 and associated with metabolic diseases such as hypertension, type 2 diabetes, and dyslipidemia. Compared with traditional weight loss methods, it is not a "quick-acting drug", but a chronic management drug that continues to act on metabolic pathways. Overseas research shows that Wegovy not only helps patients lose weight, but also improves liver steatosis, reduces cardiovascular risk and improves insulin sensitivity, which makes it show wider application prospects in the management of metabolic syndrome.

Reference materials:https://www.drugs.com